Ubrogepant is not indicated for the preventive treatment of migraine.
Avoid use in patients with end-stage renal disease.
- TRADE NAME: Ubrelvy (Allergan)
- INDICATIONS: Acute treatment of migraine with or without aura in adults
- CLASS: Calcitonin gene-related peptide (CGRP) receptor antagonist
- HALF-LIFE: ~5–7 hours
- FDA APPROVAL DATE: 12/23/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
BCRP and/or P-gp only inhibitors, CYP3A4 inhibitors, CYP3A4 inducers, Ciprofloxacin, Clarithromycin, Cyclosporine, Fluconazole, Fluvoxamine, Grapefruit Juice, Itraconazole, Ketoconazole, Phenytoin, Rifampin, St John's Wort, Verapamil - PREGNANCY: There are no adequate data on the developmental risk associated with use in pregnant women.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
